Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…
tolebrutinib
Recommended Posts
- Stroke drug may ease MS damage, animal studies suggest
- One silent MRI lesion may be enough to consider stronger MS treatment
- It may only be one life with multiple sclerosis, but it’s mine
- Certain cannabis-based therapies may help relieve spasticity in MS
- Greater disability tied to poorer cognitive function in people with RRMS